(Q33391524)

26 July 2017

title

Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease (English)

1 reference

26 July 2017

1 reference

D. Elstein

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727796

20 June 2024

G. M. Cohn

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727796

20 June 2024

N. Wang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727796

20 June 2024

M. Djordjevic

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727796

20 June 2024

C. Brutaru

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727796

20 June 2024

A. Zimran

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727796

20 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20727796

20 June 2024

publication date

19 August 2010

1 reference

full work available at URL

26 July 2017

https://api.elsevier.com/content/article/PII:S1079979610001889?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.BCMD.2010.07.008

https://api.elsevier.com/content/article/PII:S1079979610001889?httpAccept=text/plain

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCMD.2010.07.008

Blood Cells, Molecules and Diseases

20 June 2024

published in

1 reference

26 July 2017

volume

46

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

119-123

1 reference

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

26 July 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.BCMD.2010.07.008

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

20 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.BCMD.2010.07.008

Replacement therapy with imiglucerase for type 1 Gaucher's disease

20 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.BCMD.2010.07.008

A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease

20 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.BCMD.2010.07.008

Therapeutic goals in the treatment of Gaucher disease.

20 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.BCMD.2010.07.008

A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase

20 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.BCMD.2010.07.008

Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience

20 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.BCMD.2010.07.008

Quantitative CT reference values for vertebral trabecular bone density in children and young adults

20 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.BCMD.2010.07.008

Individualization of long-term enzyme replacement therapy for Gaucher disease

20 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.BCMD.2010.07.008

20 June 2024

Identifiers

1 reference

26 July 2017

1 reference